Jue Wang, PhD

Jue Wang, PhD serves as Global Head of Business Development at Insilico Medicine (3696.HK), a pioneering clinical-stage biotechnology company driven by generative artificial intelligence. Dr. Wang joined Insilico in September 2021 as Director of Business Development and was promoted to Vice President of Business Development in February 2025, before being appointed Global Head of Business Development in June 2026. Throughout her tenure, she has played a pivotal role in expanding Insilico's global commercial footprint and translating its AI-driven discoveries into high-impact industry collaborations. Before joining Insilico, Dr. Wang accumulated over a decade of profound expertise in small-molecule novel drug discovery across roles at Shanghai Hengrui Pharmaceutical and GlaxoSmithKline (GSK), with a focus in the fields of oncology and CNS (central nervous system) diseases. Dr. Wang graduated with a PhD from the Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences. She later completed her post-doctoral research practice in pharmacology at the University of California, Los Angeles (UCLA) and obtained her MBA from the University of Hong Kong. In the landmark 2.75 billion-dollar deal with Eli Lilly announced in March 2026, Dr. Wang made significant contributions by leading the professional communication and cross-functional alignment, delivering another proof of AI possibilities and AI-driven quality. In 2026 alone, Dr. Wang led multiple landmark out-licensing and global R&D collaborations both in drug discovery and AI model development with Human Longevity, Tenacia Biotechnology, ASKA Pharmaceutical, Liquid AI, CMS, Qilu Pharmaceutical, Hygtia Therapeutics, and Servier, totaling about USD 4 billion in potential deal value. Out-licensing collaborations with global partners including Menarini, TaiGen and Hisun are delivering steady results, with multiple clinical or R&D milestones reached and payments triggered.